The epithelial-mesenchymal transition (EMT) is a complex process that occurs during organogenesis and in cancer metastasis. Despite recent progress, the molecular pathways connecting the physiological and pathological functions of EMT need to be better defined. Here we show that the transcription factor Elf5, a key regulator of mammary gland alveologenesis, controls EMT in both mammary gland development and metastasis. We uncovered this role for Elf5 through analyses of Elf5 conditional knockout animals, various in vitro and in vivo models of EMT and metastasis, an MMTV-neu transgenic model of mammary tumour progression and clinical breast cancer samples. Furthermore, we demonstrate that Elf5 suppresses EMT by directly repressing the transcription of Snail2, a master regulator of mammary stem cells and a known inducer of EMT. These findings establish Elf5 not only as a key cell lineage regulator during normal mammary gland development, but also as a suppressor of EMT and metastasis in breast cancer.
be involved in EMT (refs 10-13) . These pathways often exert their effect on EMT by regulating the expression of crucial EMT-related transcription factors, including those belonging to the Snail family, ZEB1, ZEB2 and Twist1/2 (refs 2,4,14-18). However, despite recent progress, the molecular mechanisms acting upstream of these factors in different physiological and pathological contexts are not well characterized 3, 5, 18, 19 . Recent studies have also highlighted a link between EMT and the induction of stem-cell-like properties, particularly in mammary epithelial models 20, 21 . For example, it was recently reported that the EMT-inducing transcription factor Snail2 (also known as Slug) is a master regulator of mammary stem cells (MaSCs) and cancer stem cells 20 (CSCs). Thus, uncovering the regulatory mechanisms of EMT-related transcription factors should provide greater insight into the signalling programs that govern the multiple facets of mammary gland biology and tumorigenesis.
The transcription factor E74-like factor 5 (Elf5, also known as ESE-2) belongs to the Ets (E twenty-six)-domain transcription factor family 22, 23 . Ets family proteins regulate a wide spectrum of biological processes and not only contribute to physiological development and differentiation, but also possess oncogenic or tumour suppressive activities [24] [25] [26] [27] . Indeed, several Ets factors has been associated with cancer initiation, progression and metastasis [24] [25] [26] [28] [29] [30] , and expression of the Ets family member PDEF is lost in many epithelial cancers 31 . Similarly, recent studies have shown that loss of Elf5 is frequently observed in human breast cancer tissues and cell lines 32, 33 , suggesting a potential tumour suppressive role for this transcription factor.
The importance of Elf5 in normal mammary gland development is evidenced by lactation failure and a blocked alveolar morphogenesis phenotype observed in Elf5 knockout (Elf5-KO) female mice [34] [35] [36] . In addition to the well-established role of Elf5 in alveologenesis, we have also recently reported that loss of Elf5 triggers an increase in MaSCs during normal mammary gland development 37 . Although these studies have firmly established Elf5 as a master regulator of cell fate determination in the mammary gland, the functional role of Elf5 in breast cancer progression remains largely unknown. Here, we used Elf5 conditional knockout animals, multiple breast cancer models and clinical patient samples to uncover a unique role for Elf5 in suppressing EMT and metastasis through direct transcriptional repression of Snail2 in both the mammary gland epithelium and in breast cancer.
RESULTS

Elf5 knockout induces EMT in mouse mammary epithelium
Elf5-KO mammary glands exhibit completely blocked alveologenesis during pregnancy and lactation that is accompanied by increases in luminal progenitors cells 35, 36 . Elf5 loss also triggers increases in MaSCs during normal mammary gland development 37 . Given the proposed relationship between EMT and MaSCs (ref. 21) , we examined whether Elf5-KO affected the epithelial characteristics of mammary gland tissue. We observed that the mammary epithelium of Elf5-KO animals exhibited weaker and patchier E-cadherin staining in the adherens junctions when compared with wild-type (WT) animals at two pregnancy stages (P12.5 and P17.5) and on lactation day 1 ( To evaluate whether Elf5-KO induced global EMT-related changes, we performed gene expression profiling on mammary glands at lactation day 1. Microarray analyses indicated that the loss of Elf5 led to several molecular features of EMT, including upregulation of key transcriptional inducers such as Twist1, Twist2, Zeb1, Zeb2 and Snai2 ( Fig. 2a and Supplementary Fig. S1g and Table S2 ). Importantly, these changes were also observed in microarrays performed specifically on mammary epithelial cells (MECs) purified from WT and Elf5-KO animals ( Supplementary Fig. S1h ). Furthermore, gene set enrichment analysis (GSEA) indicated that four distinct EMT/CSC-related gene signatures [38] [39] [40] [41] were significantly enriched in Elf5-KO mammary epithelial tissue, strongly suggesting that Elf5 loss induces a pervasive and sustained EMT signalling program (Fig. 2b) .
Next, to directly test the functional role of Elf5 in EMT, we stably overexpressed HA-epitope-tagged Elf5 (HA-Elf5) in NMuMG mouse mammary epithelial cells (Fig. 2c) on TGF-β-induced EMT. Whereas control cells underwent marked EMT within 72 h of TGF-β treatment, Elf5-overexpressing cells retained their epithelial features and formed tighter clusters (Fig. 2e) . Accordingly, E-cadherin expression was retained in TGF-β-treated Elf5-overexpressing cells but lost in control cells, regardless of cell culture density (Fig. 2d,e and Supplementary Fig. S1i ). HA-Elf5 expression did not affect apoptosis in basal or TGF-β-treated conditions ( Supplementary Fig. S1j ). We further found that enforced HA-Elf5 expression blocked the TGF-β-induced upregulation of numerous mesenchymal genes and transcription factors, such as Cdh2, Snai2, Twist1, Twist2, Zeb1 and Zeb2 (Fig. 2f) . Taken together, these data suggest a functional role for Elf5 in inhibiting EMT in the mammary epithelium.
Elf5 knockdown in epithelial-like T47D breast cancer cells induces EMT
To investigate whether Elf5 also regulates EMT in the context of breast cancer, we analysed Elf5 expression patterns in a panel of breast cancer cell lines 42 . We found that the level of ELF5 expression was significantly reduced in cell lines characterized by both mesenchymal morphology and high metastatic potential, suggesting the potential inhibitory role of Elf5 in EMT and metastasis ( Supplementary Fig. S2a ). To test this possibility experimentally, we used short interfering RNAs (siRNAs) to knock down Elf5 in epithelial-like T47D cells, which have moderate basal levels of Elf5 expression (Fig. 3a-c and Supplementary Fig. S2a ). Elf5 knockdown induced EMT-like morphological features, such as a spindle-shaped appearance (Fig. 3d) , and led to significant reductions in E-CADHERIN, β-CATENIN and ZO-1 expression levels as well as increases in VIMENTIN and N-CADHERIN expression levels ( Fig. 3a-d) .
Moreover, E-CADHERIN and β-CATENIN were lost from cell-to-cell contacts and the number of F-actin cables were reduced in Elf5-silenced cells (Fig. 3d) . Functionally, silencing of Elf5 increased cell motility in response to prolactin (Fig. 3e) . As a complementary experiment, we induced an EMT-like process in T47D cells using the Jak kinase inhibitor AG-490 (ref. 43 ) and investigated the effect on Elf5 expression.
Here we observed that AG-490-induced EMT-like changes, including loss of cell adhesion and E-cadherin expression, were also accompanied by a marked decrease in the Elf5 expression level ( Supplementary Fig.  S2b,c) . Collectively, these data suggest that ELF5 is an enforcer of the epithelial phenotype and an inhibitor of EMT in breast cancer.
Elf5 promotes MET in MDA-MB-231 breast cancer cells
We next examined whether overexpression of Elf5 could reverse the highly metastatic, mesenchymal-like MDA-MB-231 (MDA-231) breast cancer cell line back to an epithelial state. MDA-231 cells do not express detectable endogenous Elf5 ( the epithelial maker CDH1 and decreased expression levels of the mesenchymal markers CDH2, FN1 and VIM (Fig. 4d ). Reduced expression of several EMT-related transcription factors, including TWIST1, TWIST2 and SNAI2, was observed at 12 days post-Elf5 overexpression (Fig. 4d) ; however, only SNAI2 was significantly repressed at 48h post-transduction, implicating SNAIL2 as a potential direct target of Elf5 in MET initiation (Fig. 4e) . Functionally, we observed that overexpression of Elf5 decreased the serum-responsive motility ( was consistently repressed by changes in Elf5 levels both in the mammary gland epithelium and in breast cancer cells (Figs 1m-r, 3a-b and 4a,d). Furthermore, SNAI2 is the only prominent EMTrelated transcription factor that was strongly suppressed by Elf5 overexpression within 48 h (Fig. 4e) . We thus reasoned that Elf5 may modulate epithelial phenotypes through direct suppression of SNAI2 expression. To investigate this possibility, we performed chromatin immunoprecipitation (ChIP) of HA-Elf5 in MDA-231 Elf5 cells followed by quantitative PCR (qPCR) of the SNAI2 promoter and upstream regions (Fig. 5a,b and Supplementary Table S3) . We found that HA-Elf5 ChIPs were enriched for a conserved SNAI2 promoter region (P2), but not for upstream (P3-P7) or promoter proximal (P1) regions, suggesting that the P2 region contains the primary site for Elf5 binding in vivo (Fig. 5c ). This region is well conserved across species and, importantly, contains a consensus Elf5 DNA-binding motif 45 ( Fig. 5b) . To assess the potential for Elf5 regulation of other EMT transcription factors, we performed in silico bioinformatics analyses of their promoter regions and uncovered potential Elf5-responsive elements in the TWIST1 and SNAI1 regulatory regions. However, ChIP-qPCR analyses revealed no significant enrichment of HA-Elf5 binding in these regions, suggesting that TWIST and SNAI1 are unlikely to be direct Elf5 targets in our experimental context ( Supplementary Fig. S4f,g ). To examine whether Elf5 can repress the SNAI2 promoter, we transfected WT or mutant (mutation of the Elf5 motif in P2) SNAI2 promoter reporter constructs into control or MDA-231 Elf5 cells. We found that Elf5 overexpression significantly repressed WT but not mutant SNAI2 promoter activity (Fig. 5d) . To rule out cell-line-specific effects, we also overexpressed Elf5 in MCF7 cells and observed similar repression of the SNAI2 reporter (Fig. 5e) .
Elf5 inhibits EMT through direct transcriptional repression of SNAI2
If Snai2 is an important downstream mediator of the Elf5-mediated EMT/MET phenotype, we would expect restoration of SNAIL2 expression to revert Elf5-induced cellular changes back to the parental state. Indeed, overexpression of FLAG-SNAIL2 restored the original mesenchymal appearance of epithelial-like MDA-231 Elf5 cells (Fig. 5f,g ). Accordingly, the expression levels of epithelial markers such as E-CADHERIN, β-CATENIN and ZO-1 decreased and those of mesenchymal markers such as VIMENTIN and FN1 were increased in MDA-231 Elf5-SNAIL2 cells when compared with MDA-231 Elf5 cells ( Supplementary Fig. S5a-c) . Moreover, restoration of ZO-1 membrane localization in MDA-231 Elf5 cells was lost in MDA-231 Elf5-SNAIL2 cells ( Supplementary Fig. S5c ), further suggesting a reversion of MET. Finally, overexpression of SNAIL2 also partially rescued the reduced motility of MDA-231 Elf5 cells (Fig. 5h) . Collectively, these data suggest that Elf5-induced MET is mediated by direct repression of the key EMT inducer SNAIL2. 49 . The P value was calculated by a log rank test. (f) Kaplan-Meier plots of distant metastasis-free survival of ER-patients stratified by Elf5 expression in the NKI295 clinical data set. The P value was calculated by a log rank test.
Negative correlation of ELF5 and SNAIL2 in clinical samples
To investigate whether our experimental findings could be relevant to the pathogenesis of human breast cancer, we examined Elf5 expression patterns in relevant microarray data sets that are publicly available. In two independent clinical data sets 46, 47 , we found that the ELF5 expression level was markedly reduced in hyperplasia and multiple breast tumour subtypes when compared with corresponding matched healthy tissue (Fig. 6a,b) . We next investigated whether ELF5 may also suppress SNAIL2 expression in the clinical setting. Querying the NKI295 data set 48 , we observed an inverse correlation between ELF5 and SNAI2 expression (Supplementary Fig. S6a) . Interestingly, the degree of this anti-correlation increased markedly in oestrogenreceptor-negative (ER-) patients ( Fig. 6c and Supplementary Fig. S6b) . Furthermore, immunostaining of ELF5 and SNAIL2 in a limited set of 25 primary breast tumours revealed a similar anti-correlation in expression (r = −0.457,P = 0.0245 based on staining intensity score; Pearson correlation; Fig. 6d and Supplementary Fig. S6c ). However, sample size limitations precluded clinical subtype-specific analyses of these expression patterns. We further evaluated the prognostic value of ELF5 and SNAIL2 in a large public clinical microarray database of breast tumours from 1,354 patients 49 and found trends towards favourable prognoses for ELF5-high patients and poor prognoses for SNAI2-high patients (Fig. 6e) . Interestingly, the prognostic power of both genes was again markedly increased in ER-patients, further suggesting clinical subtype-specific roles of the ELF5-SNAI2 axis (Fig. 6e) . The subtype-specific prognostic power of ELF5 was also present in the NKI295 data set, in which ELF5-low ER-patients were found to have significantly reduced distant metastasis-free survival times when compared with ELF5-high ER-patients (Fig. 6f) . When ELF5 low and SNAI2 high were used in combination, there was only a slight increase in the prognostic power (P = 0.010, Supplementary Fig. S6d ) when compared with ELF5 low alone (P = 0.013), possibly due to the strong anti-correlation of ELF5 and SNAIL2 in ER-patients. Overall, our clinical data support the experimentally described role for ELF5 as a SNAIL2 repressor and further indicate that it may function to oppose breast cancer progression.
Elf5 inhibits breast cancer metastasis
To directly investigate whether Elf5 can suppress metastasis through its ability to inhibit EMT, we used the highly lung-metastatic LM2 subline of MDA-231 (ref. 50 ). We first confirmed that Elf5 overexpression ( Supplementary Fig. S6e ) had the same effects on LM2 cells as it did on MDA-231 cells. Indeed, Elf5 induced cuboidal, clustered cellular morphologies ( Supplementary Fig. S6f ), global negative enrichment of EMT gene signatures and decreased motility in LM2 cells (Fig. 7a,b) .
We next investigated the effect of Elf5 overexpression on lung metastasis. Luciferase-labelled control or Elf5-overexpressing LM2 cells were injected intravenously into nude mice and subjected to bioluminescent imaging (BLI). LM2-Elf5 cells exhibited reduced lung metastasis abilities even at early time points (Fig. 7c,d ), implying that Elf5 may be negatively affecting the extravasation and/or early seeding of lung metastasis. Continued BLI monitoring revealed a further reduction of metastatic outgrowth in the lungs of animals injected with Elf5-overexpressing cells (Fig. 7c,d) , and histological analyses indicated a tenfold decrease in the number of metastatic lesions produced by LM2-Elf5 cells when compared with the control cells (Fig. 7e,f) . Taken together, these analyses show that Elf5 strongly inhibits breast cancer lung metastasis.
Considering the importance of the immune system in lung metastasis 51, 52 , we extended our analysis to an immunocompetent mouse model of lung metastasis. We overexpressed Elf5 in the 4T1 murine breast cancer cell line 53 ( Supplementary Fig. S7a ) and examined its ability to inhibit metastasis in vivo. Here we found that 4T1 Elf5 cells show decreased spontaneous (Fig. 7g-h , by mammary fat pad injection) as well as experimental ( Supplementary Fig. S7b , by tail vein injection) lung metastasis without affecting primary tumour growth (Supplementary Fig. S7c ). Quantitative real-time PCR (rtPCR) analysis indicated downregulation of EMT genes such as Cdh2, Snai2, Twist2 and Zeb1 in 4T1 Elf5 when compared with control cells (Supplementary Fig. S7d ), again suggesting that Elf5 functions to oppose EMT-related gene expression programs. As Elf5 overexpression was also shown to downregulate Snai2 in 4T1 cells ( Supplementary Fig. S7a,d) , we examined whether the restoration of SNAIL2 expression could rescue the inhibition of metastasis by Elf5. Accordingly, 4T1 cells overexpressing control vector, HA-Elf5, FLAG-SNAIL2 or both HA-Elf5 and FLAG-SNAIL2 ( Supplementary  Fig. S7e-g ) were generated and used for lung metastasis assays. Whereas Ef5 overexpression alone led to a significant reduction of lung metastasis (Fig. 7i,j) , combinatorial overexpression of both Elf5 and SNAIL2 fully reverted this inhibition (Fig. 7i,j) . Therefore, our studies suggest that the inhibition of metastasis by Elf5 is primarily mediated through Snail2 in 4T1 cells.
To complement our xenograft and allograft metastasis models, we next examined the effects of Elf5 on lung metastasis using the wellestablished MMTV-Neu transgenic mouse model 54 . In accordance with our earlier report 37 , immunofluorescence analysis indicated that the Elf5 conditional knockout (Elf5-KO) MMTV-Neu primary tumours were keratin-14 + whereas the WT tumours were keratin-14 − /keratin- 8 + (Fig. 8a) , suggesting a significant luminal to basal cell fate change in tumour cells on loss of Elf5. Interestingly, we also observed an increase in Snail2 expression in Elf5-KO/MMTV-Neu when compared with WT/MMTV-Neu tumours (Fig. 8a) . Similar to results obtained from xenograft and allograft models, here we observed that Elf5-KO/Neu transgenic mice exhibited a clear trend of increased lung metastasis incidence (Fig. 8b) , as well as significantly increased numbers of lung metastasis nodules (Fig. 8c) and greater lung lesion surface area (Fig. 8d,e) as compared with their WT/Neu counterparts. Furthermore, the level of Snail2 expression was strongly increased in Elf5-KO/Neu (Fig. 8e ) when compared with WT/Neu lung metastasis lesions. Finally, these results were further confirmed by independent experiments in which Elf5-overexpressing primary tumour cells derived from MMTVPyMT transgenic mice showed significantly decreased lung metastasis abilities without detectable changes in primary tumour growth following mammary fat pad injections in FVB mice ( Supplementary  Fig. S8 ). Overall, data from transgenic mice complement our findings from the NMuMG, MDA-231 and 4T1 cell line models and clinical breast cancer samples, strongly supporting the role of Elf5 as a metastasis-suppressing gene through direct targeting of Snail2.
DISCUSSION
Increasing evidence suggests that the normal genetic programs underlying various developmental processes can often be usurped in pathological conditions such as cancer metastasis 55, 56 . The functional role of EMT, a process crucial for embryonic organogenesis, serves as a leading example of this burgeoning paradigm 2, 4, 7 . Not surprisingly, physiological and pathological EMT processes share many common features and molecular regulators, and EMT studies in the context of both development and cancer may thus provide an integrative understanding of the pathological basis of malignancy.
Elf5 is well known as the master regulator of alveolar cell fate in mammary gland development 35, 36 , and recent work from our laboratory suggests a more expansive role for Elf5 in inhibiting MaSC activity 37 . However, it was not previously known whether this role of Elf5 in influencing mammary cell fate could also impact the development and progression of mammary tumours. In this report, we delineate the role of Elf5 in regulating EMT and metastasis. We have used a combination of in vitro cellular systems, bioinformatic analyses and multiple in vivo metastasis models to show that gain of Elf5 promotes a global acquisition of numerous epithelial characteristics and suppresses metastatic progression. Conversely, loss of Elf5 induces marked EMT and accelerates lung metastasis. Mechanistically we have shown that Elf5 regulates these cellular programs through its direct transcriptional repression of the key EMT transcription factor SNAIL2. Finally, clinical data set analyses suggest that this Elf5-SNAIL2 signalling axis is intact in breast cancer patients and significantly affects patient prognosis, particularly in the ER-cohort. Further clinical and functional analysis will be needed to investigate the molecular basis of this subtype-specific association and the potential involvement of the ELF5-SNAIL2 axis in other subgroups of breast cancers.
Snail2 is a transcription factor conserved across species that has been shown to play an important role in EMT during gastrulation 5 . In the breast epithelium, Snail2 is normally expressed in the basal/stemcell-enriched population in both mice and humans 57 and has been established as one of the most powerful mediators of EMT in mouse and human invasive carcinoma cells 19, [58] [59] [60] . Intriguingly, a recent study has demonstrated a critical role for Snail2 in regulating MaSC and CSC activity, particularly in cooperation with the transcription factor Sox9 (ref. 20) . Although Snail2 expression is known to be lost during the transition from MaSCs to differentiated luminal cells 20 , the underlying mechanism of this repression in normal mammary differentiation is unknown. Our present study indicates Elf5 as a crucial negative regulator of Snail2 in both mammary gland development and breast cancer. Adding to our recent observation that loss of Elf5 results in an increase in MaSC activity 37 , we have further dissected the role of the Elf5-Snail2 axis in MaSC regulation by gain-of-function overexpression of Elf5. Elf5 overexpression decreased MaSC activity, which was reverted by overexpression of Snail2 (Supplementary  Table S4 ). Conversely, the increased MaSC phenotype observed in Elf5-KO mammary epithelial cells was reversed by Snail2 knockdown (Supplementary Table S5 ). Taken together with our extensive analysis of the Elf5-Snail2 axis in EMT and metastasis, our results suggest that a high level of expression of Elf5 in the differentiated luminal lineage inhibits Snail2 expression and basal cell properties, whereas loss of Elf5 not only induces EMT and increases Snail2-dependent MaSC activity, but also promotes breast cancer metastasis (Fig. 8f) . Overall, these findings support previous studies demonstrating a tight relationship between EMT and stemness 20, 21, 40, 41, 61 . Interestingly, GSEA of our microarray data indicated that there is significant enrichment of the CSC gene signature in Elf5-KO mouse mammary glands (Fig. 2b) and, correspondingly, negative enrichment of the CSC signature in Elf5-overexpressing breast cancer cells (Fig. 7a) . Future experiments will be needed to investigate the potential role of Elf5 as an inhibitor of CSCs.
Together, our analyses have concluded that Elf5, through its direct negative regulation of Snail2, serves as a master enforcer of the epithelial cell fate. In the physiological context, this role promotes the proper identity of alveolar mammary epithelial cells, whereas in the pathological context Elf5 functions as a suppressor of EMT and cancer metastasis. Notably, Elf5 loss has been frequently detected during the early onset of disease progression at the stage of breast hyperplasia. This event may therefore represent one of the driving forces for early stage breast tumour cells to proceed with EMT and subsequent metastatic progression, thus highlighting the Elf5-Snail2 axis as a potential target for early therapeutic intervention in breast cancer progression.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper
METHODS
Animal studies. The Elf5-deficient mice generated by homologous recombination have been described previously 36 . For all experiments, Elf5 conditional knockouts (n = 5) and control littermate animals (n = 5) were used. Histological analysis, immunohistochemistry and immunofluorescence microscopy. For histological analysis, mammary gland specimens were processed as previously described 37 . For immunocytochemistry, cells were seeded onto glass coverslips and were processed as previously described 37 . Antibodies and dilutions used are listed in Supplementary Table S1 . TOPRO or DAPI was used to stain nuclei.
Molecular cloning.
The pLEX plasmids (Open Biosystems) containing complementary DNAs for control GFP, WT Elf5, MT Elf5 and FLAG-SNAIL2 were generated by routine molecular cloning techniques. The HA-tagged WT Elf5 and MT Elf5 cDNAs were subcloned from pCMV-HA vector 44 to pLEX plasmids using BamH1-Not1 restriction enzymes. The FLAG-tagged SNAIL2 cDNA was subcloned to pLEX plasmids using BamH1-Xho1 restriction enzymes. The DNA-binding deficient MT Elf5 has been described before 44 . The SNAI2 promoter (−720 to +60 region) was isolated from human genomic DNA by PCR and cloned in pGL3 basic vector (Promega, Madison) using Xho1-HindIII restriction enzymes. The mutation of the Elf5-binding site (GGA > ATG) in the human SNAI2 promoter was generated using a 2-step PCR-based approach 44 .
Cell culture and viral infection. MDA-231 and T47D cells were cultured in DMEM and RPMI-1640, respectively, and supplemented with 10% fetal bovine serum (FBS) and antibiotics. Lentivirus production was performed essentially as previously described 37 . Virally infected cells were selected with puromycin.
siRNA knockdown studies. For knockdown experiments, siRNA targeting the ELF5 gene (5 -AGCCCTGAGATACTACTATAA-3 , catalogue number GS2001) and all star siRNA negative control were purchased from Qiagen. T47D siRNA transfections were conducted using Lipofectamine RNAiMAX (Invitrogen).
Transwell migration assay and Boyden chamber invasion assay. For Transwell migration and invasion assays using MDA-231 and LM2 cells, 5 × 10 5 cells were plated on 8-µm Transwell filters (Corning). For invasion assays, inserts were coated on the inside with 1-2 mg ml −1 of Matrigel per insert. The cells were induced to migrate towards medium containing 20% FBS for 20 h (for migration assay) and 24 h or 48 h (invasion assay) in the CO 2 incubator. Non-invading cells were removed with a cotton swab. The remaining cells were fixed, stained with haematoxylin and eosin, and analysed by a bright-field microscope. Ten random fields were chosen and cell numbers were averaged. For T47D cells, 5×10 5 cells were plated. Transwell chambers were separated by membranes with 12-µm pores and FBM medium containing 500 ng ml −1 of prolactin was placed in the lower chamber. Cells were scored using a similar strategy to MDA-231 or LM2 cells.
Protein extraction and western blot analysis. Protein extracts from primary epithelial cells and cell lines were made in RIPA buffer as previously described 36 . Antibodies and dilutions used are listed in Supplementary Table S1 .
Quantitative rtPCR analyses. Total RNA was isolated from cells and mouse mammary glands using TRIzol reagent (Invitrogen) in accordance with the manufacturer's instructions. rtPCR was performed on a BioRad iCycler iQ (Bio-Rad Laboratories) or ABI 7900 96 HT series PCR machine (Applied Biosystem) using SYBR Green Supermix (Bio-Rad Laboratories). The gene-specific primer sets were used at a final concentration of 0.2 µM and their sequences are listed in Supplementary Table S2 . All rtPCR assays were performed in technical duplicate in at least three independent experiments using three different samples.
Microarray analysis. Gene expression profiles of mammary gland tissues and purified MECs from WT and Elf5-KO mice were analysed using Affymetrix GeneChip Mouse Genome 430 2.0 Arrays, following the manufacturer's instructions. Three independent sets of biological replicates of mammary gland samples and two sets of biological replications of MECs were used. Gene expression profiles of the MDA-231 or LM2 cells with or without Elf5 overexpression were determined using Agilent human GE 4x44k microarrays (Agilent, G4112F) following the manufacturer's instructions (G4140-90051).The testing RNA samples and universal human reference RNA (Strategene) were labelled with CTP-cy5 and CTP-cy3, respectively. The expression value of individual probes refers to the Log2(Cy5/Cy3) ratio.
GSEA. We used GSEA v2.0 to perform GSEA on various functional and/or characteristic gene signatures 63, 64 . Gene sets were either obtained from the MSigDB database v3.0 (September 2010 release) or from published gene signatures [38] [39] [40] [41] . Statistical significance was assessed by comparing the enrichment score to enrichment results generated from 1,000 random permutations of the gene set to obtain P values (nominal P value).
Clinical data set analysis. Raw microarray data from published studies 46, 47 were downloaded from the Gene Expression Omnibus. Raw data were normalized, log 2 transformed and median centred at 0 using Genespring GX. Only probe 220625_s_ at was used for Elf5. Differences in ELF5 expression between classes were assessed by Student's t -test without the assumption of equal variance. NKI295 gene expression data were downloaded from the Stanford Microarray Database (http://microarray-pubs.stanford.edu/wound_NKI/explore. html). The classifications included in the data set (Sorlie classification method) were used for assignment of patients into clinical breast cancer subtypes. For survival analyses, distant metastasis-free survivals, stratified by expression of the gene of interest, were presented as Kaplan-Meier plots and tested for significance using log-rank tests. The degree of correlation between ELF5 and SNAI2 patient expression patterns was assessed using Pearson correlation analysis.
Immunohistochemical analysis of breast tumour specimens. Immunohistochemistry of SNAIL2 and ELF5 was performed by the Tissue Analytic Core Facility in the Cancer Institute of New Jersey. Anti-SNAIL2 (Cell Signaling, catalogue number 9585) and anti-ELF5 (Abcam, catalogue number ab13581) were first optimized on regular human breast tissue slides using a Ventana Medical Systems Discovery XT automated immunostainer. For ELF5, thyroid tissue was used as a positive control as suggested by the company. Slides were processed as previously described 62 . Anti-SNAIL2 antibody and anti-ELF5 antibody were applied at dilutions of 1:20 and 1:100, respectively, and incubated at room temperature for 2 h.
Twenty-five primary human breast tumour samples were used for immunohistological staining in our ELF5/SNAIL2 expression correlation study. Tumour specimens used were obtained from the Cancer Institute of New Jersey with informed consent from all subjects in accordance with the institutional review boards of Princeton University and the University of Medicine and Dentistry of New Jersey. Each sample was scored as negative (0), low (1), medium (2) or high (3) according to SNAIL2 and ELF5 nuclear staining intensities. A tumour with a mean score larger than 1 was considered to be positive for the expression of the gene. Pearson's coefficient test was performed to assess statistical significance.
ChIP. MDA-231 Elf5 cells were grown to 80% confluence and cells were then crosslinked with 1% formaldehyde and processed. The crosslinking, immunoprecipitation, washing, elution, reverse crosslinking and proteinase K treatment were performed according to the manufacturer's directions described in the Magna ChIP G Chromatin Immunoprecipitation Kit from Millipore. Antibodies used were anti-HA (Abcam, catalogue number ab9110) or normal rabbit IgG. Purified immunoprecipitated DNA was used for quantitative rtPCR. Primers for ChIP-PCR are shown in Supplementary Table S3 .
Luciferase reporter assay. MDA-231 cells (5 × 10 4 ) were seeded in 24-well plates 24 h before transfection. The following day, 300-800 ng of the SNAI2 promoter reporter plasmid (WT or MT) along with 200 ng of internal control plasmid constitutively expressing Renilla-luciferase was co-transfected using Lipofectamine 2000 (Invitrogen). Cells were collected 24 h post-transfection and assayed for luciferase activity using the Glomax 96 microplate luminometer (Promega). For experiments with MCF-7 cells, cells were transfected with Elf5-expression plasmids and WT SNAI2 promoter reporter, and then processed as previously described 44 .
Primary MEC isolation, lentiviral spin infection and limiting dilution assay. Isolation and lentiviral transduction of primary mammary epithelial cells were performed as described previously 36, 65 . Snail2 short hairpin RNA (shRNA) was purchased from Sigma (catalogue number 
